iBio (IBIO) Stock Heads Up On No News: Here’s The Scoop

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is ticking into the green this morning, following up on the modest gains posted by the stock yesterday. Interestingly, there has been no news from the company. Nonetheless, chatter across message boards seems to provide clues as to why the stock is making a move upward. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Is Making A Move For The Top

As mentioned above, iBio is having a relatively strong start in the premarket hours today, but no news has been released. So, what’s the deal? Well, there are a couple of things that seem to be causing the move.

First and foremost, all over message boards we’re seeing messages like this one shared by Soemotional on Stocktwits:

$IBIO people are still a bit hesitant to buy in now….would you rather buy NOW when consolidation period was 3 months….OR do you want to buy when this stock is up already 80%….? Don’t be a fool pennietrading….buy and hold…THANK ME LATER!

Ultimately, technical traders are seeing signals that suggest IBIO will start to make a big move upward in the very near future. However, technical analysis isn’t the only thing that seems to be exciting investors about the stock.

In fact, all over message boards, we’re also seeing messages like this one from Peterbird on Stocktwits:

$IBIO January 300M Vaccines –> Speaks for IBIO Fast Pharming.

Head of Operation Warp Speed sees emergency authorization vaccine request around Thanksgiving.

Essentially, from a fundamental perspective, there’s quite a bit to be excited about. Operation Warp Speed aims to deliver 300 million COVID-19 vaccines starting in January of next year. That’s a tall order, even for the largest, most successful biotechnology companies and vaccine manufacturers. 

While IBIO is currently working on two COVID-19 vaccines, investors are starting to see what I’ve been telling you about for months. The COVID-19 vaccine candidate is valuable, the FastPharming Facility is far more valuable. 

The fact of the matter is that no other vaccine manufacturer that I know of has the ability to produce mass amounts of vaccine doses in as short a period of time as can be done in the FastPharming Facility. As long as there is a plant-based vaccine approved, the FastPharming Facility will be a key player. 

At the moment, there are several plant-based vaccines under development. The most notable of which is at the center of a partnership between GlaxoSmithKline plc (NYSE: GSK) and Medicago, which has already entered clinical trials. Should this vaccine, one of the vaccines being produced by iBio, or one of many other plant-based candidates make it to commercialization, IBIO is the prime option for manufacturing thanks to the FastPharming Facility. 

The Bottom Line

The bottom line here is simple. As far as traders are concerned, IBIO is showing signs of big gains likely ahead. Beyond the technical side of the coin, there are plenty of reasons to be excited about the company, from its own work in vaccine development to the cornerstone position it will likely have in manufacturing should another company bring a plant-based vaccine to market. All in all, IBIO stock is one to watch closely. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.